G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2020-30: COVID-19 Growth And Change
The Business Research Company’s G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2020-30: COVID-19 Growth And Change
LONDON, GREATER LONDON, UK, January 15, 2021 /EINPresswire.com/ — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The increasing prevalence of cancer is a key factor driving the growth of the granulocyte colony stimulating factor drugs market. The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of G-CSF drugs and relates services. Granulocyte colony-stimulating factor is a drug used to treat neutropenia, a disorder in which there is a lower-than-average number of white blood cells, caused by certain forms of chemotherapy. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. According to the World Health Organization (WHO), 9.6 million deaths occurred in 2018 due to cancer. About 70% of deaths from cancer occur in low- and middle-income countries. G-CSF is a class of growth factor which produces white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infection after certain forms of treatment for cancer.
The global G-CSF (Granulocyte-Colony Stimulating Factors) market declined from $7.30 billion in 2019 to $6.91 billion in 2020 at a compound annual growth rate (CAGR) of -5.27%. The decline was mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $8.33 billion in 2023 at a CAGR of 6.44%.
Here Is A List Of Similar Reports By The Business Research Company:
Oncology Drugs Market – By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
CAR-T Therapy Market – By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/car-t-therapy-market
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn
